CAMBRIDGE, Mass.-(BUSINESS WIRE)-RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA.
Scientists discover long-sought genetic mechanism for cancer progression
Action of a key lncRNA different in colon cancer versus normal colon tissue Genetics researchers from Case Western Reserve School More »
MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures
Long noncoding RNAs (lncRNAs) regulate gene expression by association with chromatin, but how they target chromatin remains poorly understood. Researchers More »
LncRNA Regulator Of Brown Fat Identified
from Asian Scientist AsianScientist (Apr. 29, 2015) - A study by researchers in Duke-NUS Graduate Medical School Singapore (Duke-NUS) has More »
An update on LNCipedia - a database for annotated human lncRNA sequences
LNCipedia collects long non-coding RNA sequences and annotation from different sources. In version 3.0, over 90,000 new transcripts were added More »
Unveiling a new factor that helps breast cancer cells to tolerate drugs
from biotechin.asia by Mohamad Moustafa Ali Breast cancer is one of the most divergent and heterogeneous genetic disorders that affects More »